SCHEMBL10326344

SCHEMBL10326344

C[Si](C)(C)OC(c1ccccc1-c1ccccc1)(c1ccccc1-c1ccccc1)[C@H]1CCCN1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
RAB9A P51151 1/20 0.43
HRH1 P35367 1/20 0.34
CHRNB2 P17787 2/20 0.33
CHRNA4 P43681 2/20 0.33
ADRA2A P08913 3/20 0.32
ADRA2B P18089 3/20 0.32
ADRA2C P18825 3/20 0.32
MAOA P21397 3/20 0.32
MAOB P27338 3/20 0.32
NISCH Q9Y2I1 1/20 0.32
GHSR Q92847 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12996878 1.00 KDM4E (0.43) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL10326853 1.00 KDM4E (0.43) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL10326338 0.83 KDM4E (0.42) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL10326633 0.82 CYP1A2 (0.48) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL2574515 0.81 CYP2D6 (0.56) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL3004482 0.81 CYP2D6 (0.56) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL1447193 0.81 CYP2D6 (0.56) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL5527635 0.80 CYP2D6 (0.40) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL5527642 0.80 CYP2D6 (0.40) KDM4ENPC1CYP1A2CYP2D6HPGD
SCHEMBL10326635 0.80 CYP1A2 (0.46) KDM4ENPC1CYP1A2CYP2D6HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8217204-B2 Catalyst for asymmetric hydrogenation TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-07-10 US disclosed
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324338-A1 CATALYST FOR ASYMMETRIC HYDROGENATION H1-0, H1-5, ADH5 KDM4E 4195/4885NPC1 2005/4885CYP1A2 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.